Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

By K. Siddiquee, Shumin M. Zhang, W. Guida, M. Blaskovich, B. Greedy, H. Lawrence, M. Yip, R. Jove, M. McLaughlin, Nicholas J. Lawrence and 2 more. Proceedings of the National Academy of Sciences of the United States of America, 2007

754 citations recorded by the source corpus.

Subfields: Oncology, Organic Chemistry, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/e4f66249cf6c7f12a571c85d0990d6a2ab4cfff4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Hua Yu
2. D. Pardoll
3. R. Jove
4. D. Gabrilovich
5. M. Karin
6. S. Grivennikov
7. T. Hirano
8. Antoni Ribas

In Pathology and Forensic Medicine

1. D. Pardoll
2. Hua Yu
3. R. Jove

Citations in the corpus

• Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. (2014, background): “they directly bind to the SH2 domain of STAT3 and prevent tyrosine phosphorylation, protein dimerization, and transcriptional activity [273].”
• STATs in cancer inflammation and immunity: a leading role for STAT3 (2009, positive): “In addition, screening of virtual compound libraries in silico against molecular models of STAT3 on the basis of its crystal structure has led to both peptide and non-peptide small molecules that disrupt STAT3 dimerization and transcriptional activit”